Cytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
Cytokinetics Issues Equity Awards as Employment Inducements Under Nasdaq Rule 5635(c)(4), Advances Momentum in Cardiovascular Drug Development Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company dedicated to developing novel therapies…
One World for Health: 78th World Health Assembly Set to Convene from 19–27 May 2025
One World for Health: Inside the 78th World Health Assembly and the Future of Global Public Health From May 19 to 27, 2025, Geneva, Switzerland, will once again become the…
WHO Partners with Universal Postal Union to Expand Global Access to Eyeglasses
WHO and Universal Postal Union Launch Global Initiative to Expand Access to Eye Care Through Postal Networks In a groundbreaking move to address the global burden of vision impairment, the…
30 Years of Progress: Mobilizing Health to End Violence Against Women and Girls
30 Years of Progress: Mobilizing the Health Sector to End Violence Against Women and Girls In the three decades since the landmark Beijing Platform for Action on Women was adopted…
BioMarin Strengthens Enzyme Capabilities Through $270 Million Acquisition of Inozyme
BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced…
Incyte Secures FDA Approval for PD-1 Inhibitor in First-Line Treatment of Anal Cancer
Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved…
Teen Scientists Win Over $9M at 75th Regeneron ISEF 2025
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International…
EU Approves Bristol Myers’ Opdivo Regimen for Resectable High-Risk NSCLC with PD-L1 ≥1%
European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has…
Merck to Present New PAH Data at ATS 2025 Conference
Merck to Present Robust Set of Pulmonary Arterial Hypertension Data at ATS 2025, Underscoring Long-Term Commitment to Innovation and Patient Outcomes Merck , known as MSD outside the United States…
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down
Leadership Transition at Novo Nordisk: CEO Lars Fruergaard Jørgensen to Step Down Amid Market Headwinds and Strategic Realignment In a significant leadership transition, Novo Nordisk A/S announced that Lars Fruergaard…
FDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused…
Merck Demonstrates Resilience with Continued Growth
Merck Delivers Resilient Growth Across All Divisions in Q1 2025, Advances Strategic Expansion with SpringWorks Acquisition Merck, the global science and technology powerhouse, began 2025 on strong footing, demonstrating solid…